WebMar 15, 2024 · INTRODUCTION The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with esophageal and gastric cancer, both in the adjuvant/neoadjuvant setting and for advanced disease. WebApr 13, 2024 · The Phase III trial (NCT05633602) will enrol 700 patients with stage four or recurrent NSCLC who previously received immunotherapy and chemotherapy. The study will investigate the combination treatment of Eli Lilly’s Cyramza (ramucirumab) and Merck’s Keytruda (pembrolizumab) compared to the standard of treatment.
UpToDate
WebApr 12, 2024 · Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow. Subscribe. April 12, 2024 , by Carmen Phillips. Results from two large clinical trials show that adding immunotherapy to standard treatment for advanced endometrial cancer, including people with stage III disease (above), improves progression-free survival. Web1 day ago · Pragmatic clinical trials (PCTs) are designed to evaluate the effectiveness of therapeutic interventions in real-life clinical situations, whereas explanatory trials test whether an intervention ... dhec south carolina wic
Pragmatica-Lung Study aims to increase accessibility to cancer …
WebRamucirumab (Cyramza®): a monoclonal antibody that targets the VEGF/VEGFR2 pathway and inhibits tumor blood vessel growth; approved for subsets of patients with non-small cell lung cancer (NSCLC), including as a first-line therapy Immunomodulators WebIndication and Important Safety Information. INDICATION. CYRAMZA as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. WebThis drug can be used along with the immunotherapy drug atezolizumab (Tecentriq) as the first treatment for liver cancer that cannot be treated by surgery or that has spread to other organs. This drug is given as an infusion into a vein (IV), typically once every 3 weeks. Ramucirumab (Cyramza) dhec septic regulations